ror-1

Radiance Biopharma Enters Exclusive License For ROR-1 Targeted Antibody Drug ConjugateRadiance Biopharma Enters Exclusive License For ROR-1 Targeted Antibody Drug Conjugate

Radiance Biopharma Enters Exclusive License For ROR-1 Targeted Antibody Drug Conjugate

BOSTON, Massachusetts, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Radiance Biopharma, Inc., ("Radiance" or the "Company"), a biotechnology company, today announced…

2 months ago